BridgeBio Pharma Price to Free Cash Flow Ratio 2018-2024 | BBIO
Historical price to free cash flow ratio values for BridgeBio Pharma (BBIO) since 2018.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| BridgeBio Pharma Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-12-20 |
26.49 |
|
0.00 |
| 2024-09-30 |
25.46 |
$-2.51 |
0.00 |
| 2024-06-30 |
25.33 |
$-2.42 |
0.00 |
| 2024-03-31 |
30.92 |
$-3.54 |
0.00 |
| 2023-12-31 |
40.37 |
$-3.25 |
0.00 |
| 2023-09-30 |
26.37 |
$-3.12 |
0.00 |
| 2023-06-30 |
17.20 |
$-3.16 |
0.00 |
| 2023-03-31 |
16.58 |
$-2.72 |
0.00 |
| 2022-12-31 |
7.62 |
$-2.88 |
0.00 |
| 2022-09-30 |
9.94 |
$-3.22 |
0.00 |
| 2022-06-30 |
9.08 |
$-3.18 |
0.00 |
| 2022-03-31 |
10.15 |
$-3.55 |
0.00 |
| 2021-12-31 |
16.68 |
$-3.54 |
0.00 |
| 2021-09-30 |
46.87 |
$-3.39 |
0.00 |
| 2021-06-30 |
60.96 |
$-3.62 |
0.00 |
| 2021-03-31 |
61.60 |
$-3.80 |
0.00 |
| 2020-12-31 |
71.11 |
$-3.45 |
0.00 |
| 2020-09-30 |
37.52 |
$-3.53 |
0.00 |
| 2020-06-30 |
32.61 |
$-2.57 |
0.00 |
| 2020-03-31 |
29.00 |
$-3.19 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.953B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
